Key Findings
- Among 51,692 NSCLCs molecularly profiled by Caris, distinct BRAF-mutant classes demonstrated divergent molecular, immune, and survival profiles, with class 1 and VUS tumors associated with improved outcomes compared with BRAF wild-type disease.
- In these studies, integrated genomic, transcriptomic, and immune profiling was shown to refine molecular classification and identify clinically relevant biomarkers of therapeutic response and prognosis in NSCLC.